SBIR Phase II: HIVbase, Data Integration Software to Support the Study of Chronic Viruses

这个小型企业创新研究第二阶段项目将为艾滋病毒研究人员提供管理和分析基因数据的进步方法。生物学领域正在发展一种危机，因为完全无结构的信息并不能增进理解。今天的艾滋病毒调查人员拥有大量用户不友好格式的研究信息、充满错误的电子表格、过时的数据库和包含数千个单独文件的目录。这些研究人员需要先进的协议来从他们杂乱无章的信息中提取价值。第一阶段可行性研究证明，拟议的解决方案在收集和分析数据之间提供了高质量的联系，这是艾滋病毒研究人员以前从未获得过的。这种联系有助于艾滋病毒研究人员做好他们的工作，并最终促进人们对我们这个时代最致命、代价最高的流行病的了解。该项目旨在通过开发将独特的数据存储和集成的能力与用于数据挖掘、分析和数据检索的新型应用程序相结合的软件来解决研究人员的问题。其目标是为研究人员提供现代查询、数据库和分析方法的组合。拟议产品的最初目标市场是由艾滋病毒研究人员及其相关设施组成的。这个市场很大，正在向多个方向发展，需要这种产品。估计有4000万人感染艾滋病毒，政府和私营组织提供的资金达到创纪录的水平。拟议产品的主要意义在于它能够帮助加速许多科学家、流行病学家和药理学家的努力，以取得与这种持续和悲惨的流行病有关的重要发现。

This Small Business Innovation Research Phase II project will provide HIV researchers with progressive approaches to manage and analyze genetic data. There is a crisis developing in biology, in that completely unstructured information does not enhance understanding. Today's HIV investigators possess massive amounts of research information in user-hostile formats, error- filled spreadsheets, outdated databases, and directories containing thousands of individual files. These researchers need advanced protocols for extracting value from their disorganized information. Phase I feasibility study proved that the proposed solution provides a quality link between collection and the analysis of data that has never before been available to HIV researchers. This link helps HIV researchers do their job and ultimately promotes understanding for the most deadly and costly epidemic of our time. This project aims to solving researchers problems through the development of software that combines the power of unique data storage and integration with novel applications for data mining, analysis, and data retrieval. The goal is to provide researchers with a combination of modern querying, database, and analysis approaches.The initial target market for the proposed product is made of HIV researchers and their associated facilities. This market is large, growing in multiple directions, and in need of this product. HIV infects an estimated 40 million people and is being funded at record levels from both government and private organizations. The major significance of the proposed product is in its ability to assist accelerate the efforts of the many scientists, epidemiologists and pharmacologists to make important discoveries relating to this on-going and tragic epidemic